Eli Lilly's Alzheimer's Drug Release Delayed for FDA Investigation

Key TakeawaysEli Lilly & Co. on Friday announced that the release of its experimental Alzheimer's drug will be delayed as the Food and Drug Administration looks more closely at its Phase 3 trial results.The drug maker said it was surprised at the decision, and that approval of the treatment won't come until after the first quarter.The news lifted shares of Biogen Inc., which already has a rival Alzheimer's medicine on the market, while shares of Eli Lilly lost ground. Shares of Eli Lilly & Co. (LLY) were d ...